Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

Multi-centre, randomised, double-blind, placebo-controlled Phase 2a study comparing low dose MM-120 (20 µg) with placebo, administered orally twice weekly for 6 weeks (12 doses) in adults with DSM-5 ADHD.

Primary purpose treatment; outcomes include safety and efficacy measures at Week 6. Actual enrolled count recorded as 53 participants.